Total amount: € 0,00
HOW TO ORDER
MINERVA UROLOGICA E NEFROLOGICA
A Journal on Nephrology and Urology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
Minerva Urologica e Nefrologica 2006 December;58(4):339-45
Linkage of elevated CaxPO4 product with inflammation in maintenance hemodialysis patients
Unit of Hemodialysis Hajar Medical, Educational and Therapeutic Center Shahrekord University of Medical Sciences Shahrekord, Iran
Aim. The aim of the paper was to elucidate whether and how, in end-stage renal disease (ESRD) patients on regular hemodialysis, the levels of C-reactive protein (CRP) correlate with CaxPO4 product; thus, a cross-sectional study was conducted on stable hemodialysis patients.
Methods. According to the severity of secondary hyperparathyroidism, each patient being treated for secondary hyperparathyroidism was given oral active vitamin D3, calcium carbonate capsule, and Rena-Gel tablet at various doses. Fasting serum 25-hydroxy, vitamin D and intact serum PTH and also serum blood urea nitrogen, serum CRP, albumin, serum calcium, phosphorus and alkaline phosphatase and also serum ferritin were measured using standard methods.
Results. There was a total of 41 patients, consisting of 29 nondiabetic hemodialysis patients and 12 diabetic hemodialysis patients. The mean patient age was 46±17.6 years. The value of serum CRP of patients was 8.6±6.6 mg/L (median 6 mg/L). The value of CaxPO4 product was 50.5±15.5 mg2/dL2 (median: 50 mg2/dL2). The present study showed a significant inverse correlation between CaxPO4 product and the age of the patients and a significant positive correlation between logarithm of serum CRP with age and also significant inverse correlations of dialysis adequacy as determined by urea reduction rate (URR) with logarithm of serum CRP and with CaxPO4 product. Furthermore, significant positive correlation of logarithm of serum CRP with CaxPO4 product was found too.
Conclusions. Our findings showed the need to pay futher attention to hyperphosphatemia and uncontrolled secondary hyperparathyroidism in maintenance hemodialysis patients.